INDICATIONS
LENVATINIB is a kinase inhibitor that is indicated for:
Hepatocellular Carcinoma (HCC): as first line therapy in patients with unresectable hepatocellular carcinoma.
Differentiated Thyroid Cancer (DTC): single agent for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC.
Renal Cell Cancer (RCC): in combination with Everolimus, for patients with advanced RCC following one prior anti-angiogenic therapy.